| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
6,7-Dihydroxy-4-phenylcoumarin targets cellular differentiation pathways, particularly in HL-60 leukemia cells. As a coumarin, it may exert its effects through multiple mechanisms including modulation of signaling pathways, enzyme inhibition, or interaction with cellular receptors. Its ability to induce differentiation of HL-60 cells suggests effects on cell cycle regulation and differentiation signaling. The compound's dihydroxy and phenyl substitutions contribute to its biological activity. Its structure is related to other coumarins with known biological activities such as esculetin and imperatorin.
|
|---|---|
| ln Vitro |
In vitro, 6,7-Dihydroxy-4-phenylcoumarin (Nordalbergin) displays potent activity in inducing differentiation of HL-60 cells. This activity makes it a compound of interest for studying cell differentiation and leukemia. Its differentiation-inducing activity is comparable to or more potent than related coumarins such as esculetin and imperatorin. The compound's effects on HL-60 cell differentiation are typically assessed by measuring cell surface markers, morphological changes, and functional assays such as NBT reduction. These in vitro activities confirm its potential for cancer and differentiation research.
|
| ln Vivo |
In vivo studies of 6,7-Dihydroxy-4-phenylcoumarin are not extensively documented. As a compound with potent differentiation-inducing activity in HL-60 cells, it may have potential for studying leukemia and other cancers in animal models. However, comprehensive in vivo efficacy and safety data are limited. The compound is primarily used in in vitro research on cell differentiation and natural product chemistry. Further research is needed to fully characterize its in vivo biological activity and therapeutic potential. The compound is intended for research use only and not for human therapeutic applications.
|
| Enzyme Assay |
For in vitro biochemical assays, 6,7-Dihydroxy-4-phenylcoumarin is evaluated for its effects on cell differentiation and enzyme activities. Cell differentiation is assessed by measuring cell surface markers (e.g., CD11b, CD14) using flow cytometry, morphological changes, and functional assays such as NBT reduction. Enzyme inhibition studies can be performed to evaluate effects on targets relevant to its biological activity. Antioxidant activity can be assessed using DPPH, ABTS, or FRAP assays. These cell-free and cell-based assays help characterize the compound's differentiation-inducing and other biological activities.
|
| Cell Assay |
In vitro cellular assays for 6,7-Dihydroxy-4-phenylcoumarin are performed using HL-60 human leukemia cells. Cells are cultured in standard media and treated with the compound at various concentrations. Cell differentiation is assessed by measuring cell surface markers CD11b and CD14 using flow cytometry. Morphological changes are observed by microscopy. Functional differentiation is assessed using NBT reduction assays. Cell viability is assessed using trypan blue exclusion or MTT assays to distinguish differentiation from cytotoxicity. These cellular assays help validate the compound's differentiation-inducing activity and characterize its mechanism of action.
|
| Animal Protocol |
In vivo animal experiments with 6,7-Dihydroxy-4-phenylcoumarin are not extensively documented. As a compound with differentiation-inducing activity in leukemia cells, it could be studied in leukemia xenograft models. Administration routes would include oral gavage, intraperitoneal injection, or intravenous injection. Efficacy endpoints would include tumor growth inhibition, differentiation markers in tumor tissues, and survival. The compound's safety and tolerability would be monitored through body weight, clinical signs, and histopathology. Researchers should consult the primary literature for any available in vivo protocols and data.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 6,7-Dihydroxy-4-phenylcoumarin are not extensively documented. As a coumarin with a molecular weight of 254.24, it is expected to have moderate oral bioavailability and good tissue distribution. The compound is soluble in chloroform, dichloromethane, ethyl acetate, DMSO, and acetone. Detailed PK parameters such as half-life, Cmax, Tmax, AUC, and protein binding are not available in the literature. The compound should be stored under recommended conditions to maintain stability.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 6,7-Dihydroxy-4-phenylcoumarin is not extensively characterized. As a natural coumarin from Dalbergia sissoo, it is generally considered to have a moderate safety profile, but comprehensive toxicity studies are limited. The compound is intended for research use only and not for human therapeutic applications. Its effects at high concentrations and potential interactions with other drugs or compounds have not been fully investigated. Researchers should follow standard laboratory safety practices when handling 6,7-Dihydroxy-4-phenylcoumarin.
|
| References | |
| Additional Infomation |
Nodabegin is a novel flavonoid compound.
6,7-Dihydroxy-4-phenylcoumarin (Nordalbergin) is a valuable research tool for studying cell differentiation, particularly in leukemia cells. Its potent activity in inducing differentiation of HL-60 cells makes it useful for investigating the mechanisms of differentiation and developing new strategies for leukemia therapy. The compound is also relevant for natural product chemistry research as a coumarin from Dalbergia sissoo. Its structure makes it an interesting model for studying structure-activity relationships in coumarin-induced cell differentiation. The compound can be employed in studies on cancer cell biology, differentiation therapy, and the development of differentiation-inducing agents. |
| Molecular Formula |
C15H10O4
|
|---|---|
| Molecular Weight |
254.2375
|
| Exact Mass |
254.057
|
| CAS # |
482-82-6
|
| PubChem CID |
5320203
|
| Appearance |
White to yellow solid
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
522.4±50.0 °C at 760 mmHg
|
| Melting Point |
244ºC
|
| Flash Point |
205.2±23.6 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.699
|
| LogP |
3.69
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
19
|
| Complexity |
384
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C(C([H])=C(C2C([H])=C([H])C([H])=C([H])C=2[H])C2=C([H])C(=C(C([H])=C12)O[H])O[H])=O
|
| InChi Key |
TZRNJQYCOSMOJS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H10O4/c16-12-6-11-10(9-4-2-1-3-5-9)7-15(18)19-14(11)8-13(12)17/h1-8,16-17H
|
| Chemical Name |
6,7-dihydroxy-4-phenylchromen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~983.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9333 mL | 19.6665 mL | 39.3329 mL | |
| 5 mM | 0.7867 mL | 3.9333 mL | 7.8666 mL | |
| 10 mM | 0.3933 mL | 1.9666 mL | 3.9333 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
